Comparative Pharmacology
Head-to-head clinical analysis: EQUAGESIC versus VALMID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EQUAGESIC versus VALMID.
EQUAGESIC vs VALMID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Equagesic is a combination of aspirin and meprobamate. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and COX-2, reducing prostaglandin synthesis. Meprobamate potentiates GABA-A receptor activity, producing anxiolytic and sedative effects.
Valproate increases gamma-aminobutyric acid (GABA) concentrations in the brain either by inhibiting GABA transaminase or by increasing glutamic acid decarboxylase activity, thereby enhancing inhibitory neurotransmission.
Adults: 1 tablet (200 mg meprobamate, 25 mg ethoheptazine citrate, 325 mg aspirin) orally 3 or 4 times daily.
250 mg orally three times daily.
None Documented
None Documented
Meprobamate: 10-12 hours in healthy adults, prolonged in liver disease; Aspirin: low doses 2-3 hours, anti-inflammatory doses 15-30 hours (saturable elimination).
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 10-20 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Meprobamate: renal (10% as unchanged drug, 80-90% as hydroxylated metabolites); Aspirin: renal (dose-dependent, 50-80% as salicyluric acid, 10% as unchanged salicylate at acidic pH).
Renal excretion accounts for >90% of elimination, primarily as unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic